Top

Published in:

01-04-2012 | Original Article

Relationship between type 2 diabetes mellitus and a novel polymorphism C698T in C5L2 in the Chinese Han population

Authors: Ying-Ying Zheng, Xiang Xie, Yi-Tong Ma, Yi-Ning Yang, Zhen-Yan Fu, Xiao-Mei Li, Xiang Ma, Bang-Dang Chen, Fen Liu

Published in: Endocrine | Issue 2/2012

Abstract

In a previous study, we reported a novel single nucleotide polymorphism (SNP) 698C>T (P233L) in the gene, C5L2. This gene has been demonstrated to encode a functional receptor of acylation-stimulating protein (ASP), a G-protein-coupled receptor (GPCR), that has been shown to influence insulin secretion in cultured pancreatic islet cells in vitro and is a stimulator of triglyceride synthesis and glucose transport in vivo. In this study, we evaluated the relationship between this novel C5L2 SNP and development of type 2 diabetes mellitus (T2DM) in the Chinese Han population. A case–control study examining Chinese Han T2DM patients (n = 554) and healthy controls (n = 648) was performed to investigate the role of the 698C>T (P233L) C5L2 polymorphism. Polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) analysis was used to determine expression of this SNP. Heterozygote carriers of the 698CT C5L2 genotype were more frequent among T2DM patients (13.5%) than controls (3.2%; P < 0.001). The frequency of 698CT heterozygote carriers was significantly higher in women (12.8%) than in male subjects (5.7%, P < 0.001). The odds ratio (OR) of T2DM for 698CT carriers was 4.675 [95% confidence interval (CI) 2.840–7.694]. After adjustment of confounding factors such as age, sex, smoking, drinking, hypertension, and triglyceride (TG), total cholesterol, high-density lipoprotein, and low-density lipoprotein levels, the difference remained significant (P < 0.001, OR 5.556, 95% CI 2.444–12.630). Furthermore, the diabetic 698CT carriers displayed an increase in their serum TG level. However, there were no significant differences observed in any of the parameters measured in the control group. We conclude that the 698CT genotype of C5L2 may be an influencing genetic factor for T2DM in the Chinese Han population. These findings also indicate that heterozygous expression of 698CT C5L2 may contribute to metabolic abnormalities.

M. Stumvoll, B.J. Goldstein, T.W. van Haeften, Type 2 diabetes: principles of pathogenesis and therapy. Lancet 365, 1333–1346 (2005)PubMedCrossRef

M.G. Pezzolesi, M. Nam, T. Nagase et al., Examination of candidate chromosomal regions for type 2 diabetes reveals a susceptibility locus on human chromosome 8p23.1. Diabetes 53, 486–491 (2004)PubMedCrossRef

S.S. Rich, Mapping genes in diabetes. Genetic epidemiological perspective. Diabetes 39, 1315–1319 (1990)PubMedCrossRef

S. Wild, G. Roglic, A. Green et al., Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabet. Care 27, 1047–1053 (2004)CrossRef

J.C. Chan, V. Malik, W. Jia et al., Diabetes in Asia: epidemiology, risk factors, and pathophysiology. JAMA 301, 2129–2140 (2009)PubMedCrossRef

H. Unoki, A. Takahashi, T. Kawaguchi et al., SNPs in KCNQ1 are associated with susceptibility to type 2 diabetes in East Asian and European populations. Nat. Genet. 40, 1098–1102 (2008)PubMedCrossRef

K. Yasuda, K. Miyake, Y. Horikawa et al., Variants in KCNQ1 are associated with susceptibility to type 2 diabetes mellitus. Nat. Genet. 40, 1092–1097 (2008)PubMedCrossRef

Tsai FJ, Yang CF, Chen CC, et al. A genome-wide association study identifies susceptibility variants for type 2 diabetes in Han Chinese. PLoS Genet. 6(2), e1000847 (2010)

F. Takeuchi, M. Serizawa, K. Yamamoto et al., Confirmation of multiple risk Loci and genetic impacts by a genome-wide association study of type 2 diabetes in the Japanese population. Diabetes 58, 1690–1699 (2009)PubMedCrossRef

10.

K. Cianflone, Z. Xia, L.Y. Chen, Critical review of acylation stimulating protein physiology in humans and rodents. Biochim. Biophys. Acta 1609, 127–143 (2003)PubMedCrossRef

11.

D. Kalant, R. Maclaren, W. Cui, R. Samanta, P.N. Monk, S.A. Laporte, K. Cianflone, C5L2 is a functional receptor for acylation stimulating protein. J. Biol. Chem. 280, 23936–23944 (2005)PubMedCrossRef

12.

R. Germinario, A.D. Sniderman, S. Manuel et al., Coordinate regulation of triacylglycerol synthesis and glucose transport by acylation stimulating protein. Metabolism 42, 574–580 (1993)PubMedCrossRef

13.

Y.Y. Zheng, X. Xie, Y.T. Ma et al., Relationship between a novel polymorphism of the C5L2 gene and coronary artery disease. Plos ONE 6(6), e20984 (2011)PubMedCrossRef

14.

X. Xie, Y.-T. Ma, Y.-N. Yang et al., Polymorphisms in the SAA1/2 gene are associated with carotid intima media thickness in healthy Han Chinese subjects: the cardiovascular risk survey. PLoS ONE 5(11), e13997 (2010)PubMedCrossRef

15.

K.G. Alberti, P.Z. Zimmet, Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabet. Med. 15(7), 539–553 (1998)PubMedCrossRef

16.

X. Xie, Y.T. Ma, Z.Y. Fu et al., Haplotype analysis of the CYP8A1 gene associated with myocardial infarction. Clin. Appl. Thromb. Hemost. 15, 574–580 (2009)CrossRef

17.

X. Xie, Y.T. Ma, Z.Y. Fu et al., Association of polymorphisms of PTGS2 and CYP8A1 with myocardial infarction. Clin. Chem. Lab. Med. 47, 347–352 (2009)PubMedCrossRef

18.

Y.N. Yang, X.L. Wang, Y.T. Ma et al., Association of interaction between smoking and CYP 2C19*3 polymorphism with coronary artery disease in a Uighur population. Clin. Appl. Thromb. Hemost. 16, 579–583 (2010)PubMedCrossRef

19.

Y. Huang, M. Xu, J. Hong, W. Gu, Y. Bi, X. Li, 607 C/A polymorphism in the promoter of IL-18 gene is associated with 2 h post-loading plasma glucose level in Chinese. Endocrine 37, 507–512 (2010)PubMedCrossRef

20.

M. Karadeniz, M. Erdogan, S. Cetinkalp, A. Berdeli, Z. Eroglu, A.G. Ozgen, Monocyte chemoattractant protein-1 (MCP-1) 2518G/A gene polymorphism in Turkish type 2 diabetes patients with nephropathy. Endocrine 37, 513–517 (2010)PubMedCrossRef

21.

C. Zhong, Z. Xiaofeng, M. Genshan et al., Association study of four variants in KCNQ1 with type 2 diabetes mellitus and premature coronary artery disease in a Chinese population. Mol. Biol. Rep. 37, 207–212 (2010)CrossRef

22.

M. Marcil, H. Vu, W. Cui et al., Identification of a novel C5L2 variant (S323I) in a French–Canadian family with familial combined hyperlipemia. Arterioscler. Thromb. Vasc. Biol. 26, 1619–1625 (2006)PubMedCrossRef

23.

T.J. Aitman, I.F. Godsland, B. Farren et al., Defects of insulin action on fatty acid and carbohydrate metabolism in familial combined hyperlipidemia. Arterioscler. Thromb. Vasc. Biol. 17(4), 748–754 (1997)PubMedCrossRef

24.

S.J. Bredie, C.J. Tack, P. Smits et al., Nonobese patients with familial combined hyperlipidemia are insulin resistant compared with their nonaffected relatives. Arterioscler. Thromb. Vasc. Biol. 17, 1465–1471 (1997)PubMedCrossRef

25.

M.C. Brouwers, J. Govers-Riemslag, C.G. Schalkwijk et al., Plasma PAI-1 levels are independently related to fatty liver and hypertriglyceridemia in familial combined hyperlipidemia, involvement of apolipoprotein E. Thromb. Res. 122, 466–472 (2008)PubMedCrossRef

26.

J.L. Goldstein, H.G. Schrott, W.R. Hazzard et al., Hyperlipidemia in coronary heart disease. II. Genetic analysis of lipid levels in 176 families and delineation of a new inherited disorder, combined hyperlipidemia. J. Clin. Invest. 52, 1544–1568 (1973)PubMedCrossRef

27.

A.F. Ayyobi, J.D. Brunzell, Lipoprotein distribution in the metabolic syndrome, type 2 diabetes mellitus, and familial combined hyperlipidemia. Am. J. Cardiol. 92(4B), 27–33 (2003)CrossRef

28.

N. Sattar, A. McConnachie, A.G. Shaper et al., Can metabolic syndrome usefully predict cardiovascular disease and diabetes? Outcome data from two prospective studies. Lancet 371, 1927–1935 (2008)PubMedCrossRef

29.

M.C.G.J. Brouwers, C.J.H. van der Kallen, N.C. Schaper et al., Five-year incidence of type 2 diabetes mellitus in patients with familial combined hyperlipidaemia. Neth. J. Med. 68, 163–167 (2010)PubMed

30.

K.H. Polderman, L.J. Gooren, H. Asscheman et al., Induction of insulin resistance by androgens and estrogens. J. Clin. Endocrinol. Metab. 79, 265–271 (1994)PubMedCrossRef

31.

K. Muraki, S. Okuya, Y. Tanizawa, Estrogen receptor alpha regulates insulin sensitivity through IRS-1 tyrosine phosphorylation in mature 3T3–L1 adipocytes. Endocr. J. 53, 841–851 (2006)PubMedCrossRef

32.

M. Maslowska, H.W. Wang, K. Cianflone, Novel roles for acylation stimulating protein/C3adesArg: a review of recent in vitro and in vivo evidence. Vitam. Horm. 70, 309–332 (2005)PubMedCrossRef

33.

K. Cianflone, Acylation stimulating protein and triacylglycerol synthesis: potential drug targets? Curr. Pharm. Dis. 9, 1397–1410 (2003)CrossRef

34.

A. Claing, S.A. Laporte, M.G. Caron, Endocytosis of G protein-coupled receptors: roles of G protein-coupled receptor kinases and beta-arrestin proteins. Prog. Neurobiol. 66, 61–79 (2002)PubMedCrossRef

35.

J.T. Tan, S. Nurbaya, D. Gardner et al., Genetic variation in KCNQ1 associates with fasting glucose and beta-cell function: a study of 3,734 subjects comprising three ethnicities living in Singapore. Diabetes 58, 1445–1449 (2009)PubMedCrossRef

36.

C. Hu, C. Wang, R. Zhang, et al. Variations in KCNQ1 are associated with type 2 diabetes and beta cell function in a Chinese population. Diabetologia 52(7), 1322–1325 (2009)

37.

S. Ullrich, J. Su, F. Ranta et al., Effects of I (Ks) channel inhibitors in insulin-secreting INS-1 cells. Pflugers Arch 451, 428–436 (2005)PubMedCrossRef

38.

B. Ahre′n, P.J. Havel, G. Pacini et al., Acylation stimulating protein stimulates insulin secretion. Int. J. Obes. 27, 1037–1043 (2003)CrossRef

Title: Relationship between type 2 diabetes mellitus and a novel polymorphism C698T in C5L2 in the Chinese Han population
Authors: Ying-Ying Zheng
Xiang Xie
Yi-Tong Ma
Yi-Ning Yang
Zhen-Yan Fu
Xiao-Mei Li
Xiang Ma
Bang-Dang Chen
Fen Liu
Publication date: 01-04-2012
Publisher: Springer US
Published in: Endocrine / Issue 2/2012
Print ISSN: 1355-008X
Electronic ISSN: 1559-0100
DOI: https://doi.org/10.1007/s12020-011-9574-y

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 2/2012

Further evidence that FSH causes bone loss independently of low estrogen

GnRH analogue use in postmenopausal hyperandrogenism: long-term remission

Erythropoietin produced by the retina: its role in physiology and diabetic retinopathy

The association of serum chemerin level with risk of coronary artery disease in Chinese adults

Early protective effect of mitofusion 2 overexpression in STZ-induced diabetic rat kidney

An ontogenic study of adrenomedullin gene expression in the rat lung, adrenal, kidney, and heart

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

At a glance: The STEP trials